|
There are two clinical trials for lung cancer. The purpose of the first
study (RTOG 0324) is to investigate the benefit and efficacy of the use
of monoclonal antibody infusions in combination with chemoradiation in
the non-small lung cancer (NSCLC) population.
Monoclonal antibody infusions help the body's immune system identify
cancer cells so that the body's own defenses can help destroy the cancer
cells. They are designed to block certain chemical pathways that lead to
tumor cell growth.
This study is for individuals with unresectable Stage IIIA/B NSCLC. This
is a Phase II trial.
The purpose of the second study (RTOG L-0127) is to evaluate the effectiveness
of selenium supplementation in the prevention of second primary lung tumors.
Selenium is a trace mineral that may help your body manufacture antioxidants
that may be beneficial in preventing the re-growth of certain tumors. It
naturally occurs in many foods such as tuna, Brazil nuts, certain meats
and grains.
Participants will be assigned by chance to one of the following two groups.
- Supplement selenium 200 micrograms for four years daily
OR
- Placebo (pills without any medication or supplement in them)
This study is for individuals who have been treated for Stage I non-small cell
lung cancer with complete surgical resection. This is a
phase III trial.
To learn about specific treatment guidelines, call the McGivney Center at the
Hospital of Saint Raphael (203) 789-3545 or e-mail Pat Garofolo, M.S., B.S.N.,
study coordinator. You may also want to contact your physician for more
information.
 Back to McGivney Center
Return Home
|
